問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉裕民

Recruiting

List

174Cases

2019-05-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-16 - 2023-09-30

Phase II

Completed
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    MK-3475

Participate Sites
5Sites

Recruiting5Sites

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2021-01-01 - 2026-03-31

Phase III

Completed
A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    Pembrolizumab; Lenvatinib

Participate Sites
5Sites

Recruiting5Sites

2019-02-01 - 2024-08-14

Phase III

Completed
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    KEYTRUDA®/LENVIMA®

Participate Sites
6Sites

Recruiting6Sites

2025-01-10 - 2031-05-31

Phase II

Active
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

  • Condition/Disease

    Gastrointestinal Cancer

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

2020-12-01 - 2024-05-24

Phase II

Completed
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

  • Condition/Disease

    Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma Biliary Tract Cancers, Pancreatic Cancer

  • Test Drug

    LenvimaR capsules/KeytrudaR injection

Participate Sites
2Sites

Recruiting2Sites

2015-12-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-05-01 - 2026-12-31

Phase III

Active
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer

  • Condition/Disease

    Metastatic Nonsquamous Non-Small-Cell Lung Cancer

  • Test Drug

    KEYTRUDA/ Lynparza

Participate Sites
6Sites

Recruiting6Sites

2022-10-01 - 2029-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-03-01 - 2028-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 5 6 7 8 9 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB